Home > Resources > Whitepapers > THE DEVELOPMENT OF A DIGITAL PLANT MATURITY MODEL TO AID TRANSFORMATION IN BIOPHARMACEUTICAL MANUFACTURING

THE DEVELOPMENT OF A DIGITAL PLANT MATURITY MODEL TO AID TRANSFORMATION IN BIOPHARMACEUTICAL MANUFACTURING

Surely, we cannot consider a manufacturing plant in isolation but need to see it in its context of a seamless, endto-end value chain from suppliers, through an internal and external manufacturing ecosystem, and all the way to the patient. This is not just about technology but also the need for people and processes within companies to adapt to the needs of the market.

Spotlight

BIOAXIS Healthcare

BIOAXIS Healthcare is one of the fastest growing healthcare service providers in Europe and beyond, specialising in patient support services.

OTHER WHITEPAPERS

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

Demystifying content marketing for the pharma industry

whitePaper | November 10, 2022

We know people don’t like to be sold to. And in the so-called ‘attention economy’, it is more important than ever that your business can utilise meaningful marketing and advertising practices to engage with your customers and secure their attention.

Utilizing Multi-parameter Epitope Binning to Understand aTherapeutic Antibody’s Mechanism of Action

whitePaper | January 20, 2023

Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy.

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.